Publications by authors named "Stephen B Heitner"

Claim this Profile

Mentions over time

Mentions by platform

Video Views

12,212

Total Likes

107

Extended Reach

13,345

Social Features

6
M
Mode of death and outcomes of implantable cardioverter defibrillators in transthyretin amyloid cardiomyopathy.
Zack Dale, Lana Al-Rashdan, Miriam Elman, Pranav Chandrashekar, Stephen B Heitner, Babak Nazer, Ahmad Masri

Int J Cardiol· February 2022

Videos about Article: user user user 1

4 2

View All Article and Social Media Activity
T
Toward a Quantitative Understanding of Aficamten Clinical Pharmacology: Population Pharmacokinetic Modeling.
Donghong Xu, Hanbin Li, Stephen B Heitner, Daniel L Jacoby, Stuart Kupfer

CPT Pharmacometrics Syst Pharmacol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Aficamten Compared With Metoprolol on Echocardiographic Measures in Symptomatic Obstructive Hypertrophic Cardiomyopathy: MAPLE-HCM.
Sheila M Hegde, Xiaowen Wang, Pablo Garcia-Pavia, Stoyan Getchevski, Ahmad Masri, Stephen B Heitner

J Am Coll Cardiol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Aficamten in Children and Adolescents With Obstructive Hypertrophic Cardiomyopathy: Study Design and Rationale of CEDAR-HCM.
Juan Pablo Kaski, Paul F Kantor, Stephanie J Nakano, Iacopo Olivotto, Mark W Russell, Stephen B Heitner

Circ Heart Fail· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Aficamten in Women Compared with Men with Obstructive Hypertrophic Cardiomyopathy in SEQUOIA-HCM.
Xiaowen Wang, Maria A Pabon, Tracy T Makuvire, Reziwanguli Maimaiti, Theodore P Abraham, Stephen B Heitner

Circ Heart Fail· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Aficamten in Obstructive Hypertrophic Cardiomyopathy: A Multidomain, Patient-Level Analysis of the MAPLE-HCM Trial.
Andrew Wang, Pablo Garcia-Pavia, Ahmad Masri, Bela Merkely, Michael E Nassif, Stephen B Heitner

J Am Coll Cardiol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization and Application of Novel Exercise Recovery Patterns That Reflect Cardiac Performance: A Substudy of the SEQUOIA-HCM Trial.
Joseph Campain, Catharine Griskowitz, Chloe Newlands, Brian L Claggett, Ian J Kulac, Stephen B Heitner

Circulation· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of aficamten in patients with obstructive hypertrophic cardiomyopathy and mild symptoms: results from the SEQUOIA-HCM trial.
Martin S Maron, Juan Ramon Gimeno, Josef Veselka, Roberto Barriales-Villa, Brian L Claggett, Stephen B Heitner

Eur Heart J· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Omecamtiv Mecarbil in Heart Failure With Reduced Ejection Fraction According to Age: The GALACTIC-HF Trial.
Henri Lu, Brian L Claggett, G Michael Felker, John J V McMurray, John R Teerlink, Stephen B Heitner

JACC Heart Fail· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: Effect of Hepatic Impairment or Renal Impairment on the Pharmacokinetics of Aficamten.
Donghong Xu, Justin D Lutz, Punag Divanji, Jianlin Li, Youcef Benattia, Stephen B Heitner

Clin Pharmacokinet· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Aficamten or Metoprolol Monotherapy for Obstructive Hypertrophic Cardiomyopathy.
Pablo Garcia-Pavia, Martin S Maron, Ahmad Masri, Bela Merkely, Michael E Nassif, Stephen B Heitner

N Engl J Med· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Efficacy of Aficamten in Patients With Nonobstructive Hypertrophic Cardiomyopathy: A 96-Week Analysis From FOREST-HCM.
Ahmad Masri, Mark V Sherrid, Lubna Choudhury, Pablo Garcia-Pavia, Christopher M Kramer, Stephen B Heitner

J Card Fail· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reply to: Correction to external evaluation of a commercial artificial intelligence-augmented digital auscultation platform in valvular heart disease detection using echocardiography as reference standard.
Valentina Roquemen-Echeverri, Peter G Jacobs, Evan F Shalen, Peter M Schulman, Stephen B Heitner

Int J Cardiol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Aficamten Treatment for Symptomatic Obstructive Hypertrophic Cardiomyopathy: 48-Week Results From FOREST-HCM.
Sara Saberi, Theodore P Abraham, Lubna Choudhury, Roberto Barriales-Villa, Perry M Elliott, Stephen B Heitner

JACC Heart Fail· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Serum magnesium and outcomes in heart failure with reduced ejection fraction: the GALACTIC-HF trial.
Misato Chimura, Kieran F Docherty, Pardeep S Jhund, Mingming Yang, Ryohei Ono, Stephen B Heitner

Eur Heart J· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Low incidence of atrial fibrillation in patients with obstructive hypertrophic cardiomyopathy treated with aficamten: An analysis from the REDWOOD-HCM, SEQUOIA-HCM, and FOREST-HCM trials.
Ethan J Rowin, Martin S Maron, Iacopo Olivotto, Caroline J Coats, Theodore P Abraham, Stephen B Heitner

Heart Rhythm· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of Aficamten in Patients with Obstructive Hypertrophic Cardiomyopathy and Mild Symptoms: Results from the SEQUIOA-HCM Trial.
Martin S Maron, Juan Ramon Gimeno, Josef Veselka, Roberto Barriales-Villa, Brian L Claggett, Stephen B Heitner

Eur Heart J· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Evaluation of the Effect of Aficamten on QT/QTc Interval in Healthy Participants.
Neha Maharao, Donghong Xu, Tyrell J Simkins, Owen Bowles, Genzhou Liu, Stephen B Heitner

Clin Transl Sci· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Concomitant Aficamten and Disopyramide in Symptomatic Obstructive Hypertrophic Cardiomyopathy.
Ahmad Masri, Martin S Maron, Theodore P Abraham, Michael E Nassif, Roberto Barriales-Villa, Stephen B Heitner

JACC Heart Fail· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Hepatic Impairment or Renal Impairment on the Pharmacokinetics of Aficamten.
Donghong Xu, Justin D Lutz, Punag Divanji, Jianlin Li, Youcef Benattia, Stephen B Heitner

Clin Pharmacokinet· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Aficamten vs Metoprolol for Obstructive Hypertrophic Cardiomyopathy: MAPLE-HCM Rationale, Study Design, and Baseline Characteristics.
Pablo Garcia-Pavia, Ozlem Bilen, Melissa Burroughs, Juan Pablo Costabel, Edileide de Barros Correia, Stephen B Heitner

JACC Heart Fail· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
External evaluation of a commercial artificial intelligence-augmented digital auscultation platform in valvular heart disease detection using echocardiography as reference standard.
Valentina Roquemen-Echeverri, Peter G Jacobs, Evan F Shalen, Peter M Schulman, Stephen B Heitner

Int J Cardiol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Aficamten and Cardiopulmonary Exercise Test Performance: A Substudy of the SEQUOIA-HCM Randomized Clinical Trial.
Matthew M Y Lee, Ahmad Masri, Michael E Nassif, Roberto Barriales-Villa, Theodore P Abraham, Stephen B Heitner

JAMA Cardiol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of Aficamten on Disease and Symptom Burden in Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCM.
Martin S Maron, Ahmad Masri, Michael E Nassif, Roberto Barriales-Villa, Theodore P Abraham, Stephen B Heitner

J Am Coll Cardiol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Standard-of-Care Medication Withdrawal in Patients With Obstructive Hypertrophic Cardiomyopathy Receiving Aficamten in FOREST-HCM.
Ahmad Masri, Lubna Choudhury, Roberto Barriales-Villa, Perry Elliott, Martin S Maron, Stephen B Heitner

J Am Coll Cardiol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Qualitative interview study of patient-reported symptoms, impacts and treatment goals of patients with obstructive hypertrophic cardiomyopathy.
Supriya Shore, Claire Ervin, Katherine Kosa, Sheri Fehnel, Lisa Salberg, Stephen B Heitner

BMJ Open· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis